News on companies and Pfizer

Pfizer to halt development of closely watched weight-loss drug

Read on: Financial Times

Pfizer scraps daily weight loss pill after liver injury in one patient

Read on: CNBC News

Pfizer Ends Development of Its Obesity Pill

Read on: Time

Why Pfizer ended testing on once-daily weight-loss pill treatment

Read on: NBC News

Pfizer will end development of weight-loss pill over fears about its impact to the liver

Read on: Independent

Pfizer ends development of potential pill obesity treatment

Read on: The Washington Times

Stocks making the biggest moves premarket: Apple, Nvidia, Goldman Sachs, Pfizer and more

Read on: CNBC News

Pfizer will end development of daily anti-obesity pill due to liver injury

Read on: The Hill

Pfizer just had a big setback in its race for an Ozempic competitor

Read on: Quartz

Stock Movers: Intel, Apple, Pfizer.com

Read on: Bloomberg

Stocks making the biggest moves premarket: Walmart, Target, Apple, Pfizer, Eli Lilly, Ford and more

Read on: CNBC News

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Read on: Fast Company

Pfizer Set to Raise $3.3 Billion in Final Haleon Stake Sale

Read on: Bloomberg

Pfizer CEO says he's prepared to shift manufacturing to the U.S. amid tariff threats

Read on: Quartz

Pfizer quietly made some big DEI changes

Read on: Quartz

Pfizer hires ex-FDA drug chief as top doctor

Read on: The Hill

Pfizer CEO 'disappointed' by Kennedy's refusal to rebut claims on jab risks

Read on: Financial Times

Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup

Read on: Quartz

Pfizer to pay $59.7 million over kickbacks for migraine drug

Read on: CNBC News

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up

Read on: Quartz

Pfizer's Strong Quarter Bolsters CEO's Comeback Efforts

Read on: The Wall Street Journal

Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company

Read on: CNBC News

Pfizer's guidance bump will not heal deeper wounds

Read on: Financial Times